Fundamental Analysis of HISTOGEN INC(NASDAQ:HSTO) stock

Fundamental Rating

Overall HSTO gets a fundamental rating of 3 out of 10. We evaluated HSTO against 587 industry peers in the Biotechnology industry. HSTO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HSTO is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year HSTO has reported negative net income.

HSTO had a negative operating cash flow in the past year.

HSTO had negative earnings in each of the past 5 years.

HSTO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -89.51%, HSTO is not doing good in the industry: 75.58% of the companies in the same industry are doing better.

The Return On Equity of HSTO (-130.43%) is worse than 66.50% of its industry peers.

		Industry Rank	Sector Rank
ROA	-89.51%
ROE	-130.43%
ROIC	N/A

ROA(3y)-79.39%

ROA(5y)-75.22%

ROE(3y)-128.82%

ROE(5y)-120.14%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 19836.80%, HSTO belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.

HSTO's Gross Margin has improved in the last couple of years.

HSTO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	19836.8%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y6.8%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

HSTO does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for HSTO has been increased compared to 1 year ago.

The number of shares outstanding for HSTO has been increased compared to 5 years ago.

The debt/assets ratio for HSTO has been reduced compared to a year ago.

2.2 Solvency

HSTO has an Altman-Z score of -11.61. This is a bad value and indicates that HSTO is not financially healthy and even has some risk of bankruptcy.

HSTO's Altman-Z score of -11.61 is on the low side compared to the rest of the industry. HSTO is outperformed by 81.35% of its industry peers.

HSTO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-11.61

ROIC/WACCN/A

WACC9.53%

2.3 Liquidity

A Current Ratio of 8.54 indicates that HSTO has no problem at all paying its short term obligations.

With a decent Current ratio value of 8.54, HSTO is doing good in the industry, outperforming 66.67% of the companies in the same industry.

HSTO has a Quick Ratio of 8.54. This indicates that HSTO is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of HSTO (8.54) is better than 66.83% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.54
Quick Ratio	8.54

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

HSTO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.01%, which is quite impressive.

Looking at the last year, HSTO shows a very negative growth in Revenue. The Revenue has decreased by -99.56% in the last year.

The Revenue for HSTO have been decreasing by -36.10% on average. This is quite bad

EPS 1Y (TTM)41.01%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q68.39%

Revenue 1Y (TTM)-99.56%

Revenue growth 3Y-30.95%

Revenue growth 5Y-36.1%

Revenue growth Q2Q0%

3.2 Future

HSTO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.21% yearly.

HSTO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 85.81% yearly.

EPS Next Y26.45%

EPS Next 2Y9.45%

EPS Next 3Y4.01%

EPS Next 5Y30.21%

Revenue Next Year-99.88%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y85.81%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

HSTO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year HSTO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y9.45%

EPS Next 3Y4.01%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

HSTO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

HISTOGEN INC

NASDAQ:HSTO (10/4/2023, 7:13:37 PM)

After market: 0.6531 0 (-0.74%)

0.658

+0.15 (+29.27%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.81M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-89.51%
ROE	-130.43%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	19836.8%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	8.54
Quick Ratio	8.54
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)41.01%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y26.45%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-99.56%

Revenue growth 3Y-30.95%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

HISTOGEN INC (HSTO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens